Physician profile
Sara Husain
NPI 1689908501
$4,210.61
in general payments reported to CMS, 2019-2025
28 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2021: $29.95 · 2022: $176 · 2023: $1,100 · 2024: $1,043 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $837.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $610.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $500.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $341.42 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $219.96 | 2021-2023 | Trelegy Ellipta |
| Abiomed | $200.94 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $189.76 | 2024-2025 | |
| Convatec INC. | $148.61 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $127.10 | 2022-2025 | Eliquis |
| Lundbeck LLC | $125.34 | 2023-2024 | Rexulti |
| Amgen INC. | $114.65 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $114.10 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $97.61 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.42 | 2019-2024 | Stiolto Respimat |
| Lilly USA, LLC | $85.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $71.75 | 2023-2025 | Gemtesa, Aptiom |
| Janssen Pharmaceuticals, INC | $64.22 | 2019-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $54.63 | 2025 | Strensiq |
| Merck Sharp & Dohme LLC | $45.55 | 2019 | |
| Abbott Laboratories | $36.64 | 2025 | Freestyle Libre 3 |
| Philips North America LLC | $20.83 | 2022 | |
| Acadia Pharmaceuticals INC | $20.42 | 2023 | Nuplazid |
| Amarin Pharma, INC. | $20.27 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.90 | 2025 | Voquezna |
| Averitas Pharma INC. | $16.77 | 2023 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.89 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $15.87 | 2024 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $8.19 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.